At present, China's influenza has entered the epidemic season. At the same time, the epidemic situation in COVID-19 continues to spread, and the risk of imported epidemic situation persists. 1October 4th, 165438+ The National Health and Family Planning Commission issued the "Influenza Diagnosis and Treatment Plan (2020 Edition)", which gave authoritative suggestions on influenza diagnosis and treatment under the normalization of epidemic prevention and control. Lianhua Qingwen Capsule (granule) was once again included in the recommended drug for treating influenza, which is the 25th time that Lianhua Qingwen Capsule has been included in the national diagnosis and treatment plan.
This year's flu season, COVID-19 epidemic struck, and the task of prevention and control is even more arduous. In order to comprehensively promote influenza science education and enhance the public's awareness of influenza prevention and control, the activity of "Understanding Cold and Preventing Influenza-Popular Science" jointly sponsored by Zhong Nanshan, Wang Chen, Gaofu, Liu Youning and Liu Qingquan was launched again a few days ago. At the beginning of the activity, Liu Qingquan, deputy head of the National Expert Group on Prevention and Control of Traditional Chinese Medicine in COVID-19, spoke highly of the advantages of Lianhua Qingwen and other traditional Chinese medicines in treating influenza. "In recent studies, drugs represented by Lianhua Qingwen not only have certain antiviral effects, but more importantly, they can effectively improve inflammation from the pathological environment. Drugs that clear away heat, detoxify and eliminate dampness have a good effect on sudden respiratory infectious diseases. "
Lianhua Qingwen prescription conforms to influenza syndrome.
"Influenza Diagnosis and Treatment Plan (2020 Edition)" recommends that Lianhua Qingwen be used to treat influenza with wind-heat invading the body, exterior cold invading the interior and heat poisoning invading the lungs. Lianhua Qingwen Prescription conforms to its pathogenesis characteristics and treatment rules, and draws lessons from Maxing Shigan Decoction written by Zhang Zhongjing in Han Dynasty, Rhubarb written by Wu Youke in Ming Dynasty and Yinqiao Powder written by Wu Jutong in Qing Dynasty. Among them, Herba Ephedrae and Herba Menthae can dispel wind-heat exogenous diseases; Flos Lonicerae, Fructus Forsythiae, Radix Isatidis and Rhizoma Osmundae can treat sore throat; Almond and houttuynia cordata can cure cough and expectoration; Gypsum and rhubarb can clear lung heat, so that the heat toxin in the patient's body can be discharged from the stool. The whole prescription has a good effect on typical flu symptoms such as fever or high fever, cough, phlegm and sore throat.
Lianhua Qingwen has broad-spectrum antagonistic effect on influenza virus.
The therapeutic effect of Lianhua Qingwen on influenza has been confirmed by a large number of basic and clinical studies. Experiments by Chinese Academy of Traditional Chinese Medicine, State Key Laboratory of Respiratory Diseases of Guangzhou Institute of Respiratory Health and other scientific research institutions have proved that Lianhua Qingwen has a good inhibitory and antagonistic effect on influenza A virus (H 1N 1, H3N2) and influenza B virus. The type of virus it acts on conforms to the main influenza virus types of infected people in this year's influenza diagnosis and treatment plan. Evidence-based medical research has also confirmed that Lianhua Qingwen has no difference with oseltamivir in its anti-A H 1N 1 virus H 1N 1, and its antipyretic time and relieving symptoms such as cough, sore throat, fatigue and muscle ache are better than oseltamivir.
It has played an important role in preventing and controlling COVID-19 and clearing the epidemic with flowers.
Lianhua Qingwen Capsule (granule), as one of the three major drugs, is an effective drug for treating COVID-19. Approved by the State Administration of Pharmaceutical Products for the treatment of "mild and common type in novel coronavirus", it was recommended by the state and more than 20 provinces and cities in COVID-19, and became the most recommended Chinese patent medicine.
The prospective, randomized controlled and multicenter clinical study of Lianhua Qingwen Capsule (Granule) in the treatment of novel coronavirus, which was jointly participated by academicians Zhong Nanshan, Li Lanjuan, Zhang Boli and Wuhan University People's Hospital, showed that the application of Lianhua Qingwen Capsule (Granule) could improve the disappearance rate of clinical symptoms, shorten the duration of clinical symptoms, significantly improve the improvement rate of pulmonary imaging (CT), significantly improve the clinical cure rate and reduce the proportion of severe cases. This shows that Lianhua Qingwen can improve the clinical symptoms and prognosis of COVID-19 patients. In the post-epidemic era, the prevention and control of COVID-19 epidemic will continue to play more roles.